Key result
Soluble platelet-activation markers including sCD40L, soluble GPV, MMP-9, PF4, sP-selectin, and SCUBE1 were significantly elevated in patients with coronary artery disease versus healthy subjects.
Why the study?
Given the role of platelets in CAD, assessing soluble platelet-activation markers may be useful to improve thrombotic risk stratification.
Are soluble platelet-activation markers elevated in patients with coronary artery disease compared to healthy subjects?
Population
Patients with CAD, including ACS and chronic coronary disease, and healthy subjects
Comparison
Patients with CAD vs healthy subjects
Design
Systematic review and meta-analysis
Authors
Loading...
May aid CAD thrombotic risk stratification; extends meta-analytic evidence but leaves open clinical utility pending prospective validation.
Meta-Analysis
Are soluble platelet-activation markers elevated in patients with coronary artery disease compared to healthy subjects?
Soluble platelet-activation markers including sCD40L, soluble GPV, MMP-9, PF4, sP-selectin, and SCUBE1 are significantly elevated in patients with CAD, particularly in ACS, suggesting potential utility for thrombotic risk stratification.
Brambilla et al. (2025) conducted a meta-analysis in Coronary artery disease. Soluble platelet-activation markers vs. Healthy subjects was evaluated on Levels of soluble platelet-activation markers. Soluble platelet-activation markers including sCD40L, soluble GPV, MMP-9, PF4, sP-selectin, and SCUBE1 were significantly elevated in patients with coronary artery disease versus healthy subjects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: